Test Price
2,800 AED✅ Home Collection Available
RECQL Gene Breast Cancer Susceptibility Genetic Test in UAE – 2,800 AED – DNA Labs UAE
Executive Summary & Core Metrics
Diagnostic Accuracy
99.9% clinical sensitivity via Next‑Generation Sequencing (NGS) under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Specimen Collection
VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM–11 PM).
Post‑Test Guidance
Telephonic result interpretation by a licensed Consultant Medical Geneticist.
Insurance & Billing
Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This test uses Next‑Generation Sequencing (NGS) to analyze the complete coding region and splice‑site boundaries of the RECQL gene. The assay detects pathogenic and likely‑pathogenic germline variants that confer elevated susceptibility to hereditary breast cancer. Full‑gene coverage eliminates the blind spots of hotspot‑only methods and provides clinically actionable results for patients with a strong family history of breast or ovarian cancer.
| Feature | RECQL NGS Test (DNA Labs UAE) | Alternative PCR‑Based Single‑Gene Assay |
|---|---|---|
| Clinical Sensitivity | 99.9% – full exon and splice‑site coverage | ~85% – limited to known hotspot mutations |
| Method | Next‑Generation Sequencing (NGS) on Illumina platform | Allele‑specific PCR or Sanger sequencing |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Variant Detection Scope | Single‑nucleotide variants, indels, splice‑site mutations | Only pre‑selected hotspot mutations |
Physician Insight & Safety Protocols
“A positive RECQL result does not equate to a cancer diagnosis; it indicates a predisposition that warrants personalized surveillance and preventive measures. Every genetic finding must be contextualized within the patient’s full pedigree and clinical history. Negative results do not eliminate all risk, and continued standard screening remains essential.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Pre‑Test Advisory
Clinical Advisory
Do not alter or discontinue any prescribed medication, hormone therapy, or chemoprevention regimen without consulting your treating physician. This test is intended for risk assessment and does not replace clinical diagnosis or routine oncology care.
Exclusion Criteria & Emergency Red Flags
- Not indicated for individuals under 18 years of age without explicit informed consent from a legal guardian, in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Pregnant women seeking prenatal genetic information must undergo dedicated pre‑test genetic counseling before sample collection.
- Patients with uncontrolled severe psychiatric illness who cannot provide voluntary informed consent should be evaluated by a mental health professional prior to testing.
- If you experience suicidal ideation, panic attacks, or severe psychological distress after receiving test results, seek immediate emergency medical care at the nearest hospital.
Patient FAQ & Clinical Guidance
1. What is the RECQL gene test and why is it performed?
The RECQL gene test uses NGS to detect inherited pathogenic variants in the RECQL gene. RECQL encodes a DNA helicase involved in genome stability; loss‑of‑function mutations increase the risk of developing breast cancer, particularly in families with multiple affected members.
2. Who should consider this genetic test?
This test is appropriate for individuals with a personal or family history suggestive of hereditary breast cancer: early‑onset breast cancer (≤45 years), bilateral breast cancer, triple‑negative breast cancer, multiple relatives with breast or ovarian cancer, or a known RECQL mutation in the family.
3. How is the sample collected and when will results be available?
A peripheral whole‑blood sample (2–5 mL in an EDTA tube), extracted DNA, or a dried blood spot on an FTA card is accepted. Home collection by a trained phlebotomist is available daily from 8 AM to 11 PM. Results are reported within 3–4 weeks of sample receipt at the laboratory.
4. How are results delivered and interpreted?
A detailed clinical report is issued by a Consultant Medical Geneticist. A telephonic post‑test counseling session is scheduled to explain the results, discuss risk management options, and coordinate any necessary referrals to surgical oncology or high‑risk breast clinics.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All genetic data are processed and stored in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient specimens are anonymized, and genomic data are encrypted both at rest and in transit. Access to genetic results is restricted to authorized clinical personnel and the patient. No data are shared with third parties without explicit written consent, except where required by UAE law. The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License 1143.
Clinical & Logistical Metadata
| Test Name | RECQL Gene Breast Cancer Susceptibility Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card dried blood spot |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding exons and flanking splice‑site regions |
| ICD-10-CM Code | Z15.01 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians